Join Growin Stock Community!

Ionis pharmaceuticals, inc.IONS.US Overview

US StockHealthcare
(No presentation for IONS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IONS AI Insights

IONS Overall Performance

IONS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IONS Recent Performance

-0.08%

Ionis pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IONS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IONS Key Information

IONS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IONS Profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Price of IONS

IONS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IONS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.92
PB Ratio
21.13
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
98.31%
Net Margin
-40.41%
Revenue Growth (YoY)
33.83%
Profit Growth (YoY)
33.70%
3-Year Revenue Growth
10.21%
3-Year Profit Growth
9.65%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.92
PB Ratio
21.13
Price-to-FCF
-
Gross Margin
98.31%
Net Margin
-40.41%
Revenue Growth (YoY)
33.83%
Profit Growth (YoY)
33.70%
3-Year Revenue Growth
10.21%
3-Year Profit Growth
9.65%

  • When is IONS's latest earnings report released?

    The most recent financial report for Ionis pharmaceuticals, inc. (IONS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IONS's short-term business performance and financial health. For the latest updates on IONS's earnings releases, visit this page regularly.

  • What is the operating profit of IONS?

    According to the latest financial report, Ionis pharmaceuticals, inc. (IONS) reported an Operating Profit of -214.46M with an Operating Margin of -105.47% this period, representing a decline of 93.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IONS's revenue growth?

    In the latest financial report, Ionis pharmaceuticals, inc. (IONS) announced revenue of 203.33M, with a Year-Over-Year growth rate of -10.26%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IONS have?

    As of the end of the reporting period, Ionis pharmaceuticals, inc. (IONS) had total debt of 2.04B, with a debt ratio of 0.58. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IONS have?

    At the end of the period, Ionis pharmaceuticals, inc. (IONS) held Total Cash and Cash Equivalents of 372.26M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IONS go with three margins increasing?

    In the latest report, Ionis pharmaceuticals, inc. (IONS) did not achieve the “three margins increasing” benchmark, with a gross margin of 96.1%%, operating margin of -105.47%%, and net margin of -112.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IONS's profit trajectory and future growth potential.

  • Is IONS's EPS continuing to grow?

    According to the past four quarterly reports, Ionis pharmaceuticals, inc. (IONS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.43. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IONS?

    Ionis pharmaceuticals, inc. (IONS)'s Free Cash Flow (FCF) for the period is -159M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 12.26% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.